Alvotech Confirms Plans for NASDAQ Stockholm Listing
Alvotech, a leader in the biotech sector known for developing biosimilar medicines, has announced plans to broaden its reach by listing Swedish Depository Receipts (SDRs) on Nasdaq Stockholm. The company's leadership sees this as a strategic opportunity to widen its investor base and raise visibility among European and Nordic institutional investors. This decision comes after Alvotech's acquisition of Xbrane Biopharma AB's R&D operations, increasing its development capabilities significantly.
Importance of the Listing
Róbert Wessman, Founder, Chairman, and CEO of Alvotech, emphasized the significance of the Nasdaq Stockholm listing, stating it aligns with the company's ambitions in global biosimilar development and manufacturing. This move not only establishes Alvotech’s presence within the Swedish life sciences industry but also opens doors for broader recognition within the Nordic and European markets. With increasing interest from investors in biotech opportunities, Alvotech aims to position itself as an attractive option for those seeking investments in this vital sector.
Details of the Offering
Key Features of the SDR Offering
The Offering is set to take place between May 9 and May 16, and during this application period, the price of each SDR will be determined by the average trading price of the company's ordinary shares on Nasdaq Iceland during this time. A discount of ten percent will be applied, and the maximum price is capped at SEK 90 per SDR. The anticipated gross proceeds from the Offering stand at approximately SEK 30 million, with 441,600 SDRs to be offered in total.
First Day of Trading and Anticipated Outcomes
The initial trading of these SDRs on Nasdaq Stockholm is expected to commence on May 19. The Company has undertaken significant steps to prepare for this transition, including securing approval for a prospectus from the Swedish Financial Supervisory Authority. This prospectus details essential terms and conditions and highlights the expected positive impacts of this move on both institutional and retail investors across Sweden and the broader region.
Strategic Expansion Efforts
With the acquisition of Xbrane's R&D operations, Alvotech aims to enhance its capacity in research and development and tap into seasoned life-science professionals in Sweden. This not only strengthens the company’s innovation capabilities but also fosters a richer talent pool. The calculated expansion strategy is designed to support Alvotech’s growth trajectory and enhance its standing within the competitive landscape of European biotech.
Free SDR Conversion for Existing Shareholders
Alvotech plans to provide its current shareholders with a unique opportunity to convert existing shares into SDRs for free during the first year of trading. The company will cover conversion fees charged by Euroclear Sweden and DNB Bank, making this transition smoother for shareholders eager to partake in the new listing.
Anticipated Timetable for the Offering
The offering timeline includes public applications from May 9 to May 16, and the outcome of the Offering is expected to be released on May 16, just before the initial trading begins. This schedule is crucial for stakeholders, informing them of significant dates that will impact their investment strategies as the company moves forward.
About Alvotech
Founded by Robert Wessman, Alvotech is dedicated to the production of biosimilar medications aimed at providing cost-effective healthcare solutions globally. With two biosimilars already in the market and a diverse pipeline of future projects targeting autoimmune disorders and other serious health conditions, the company has established important partnerships across the globe, including regions such as the U.S., Europe, and Asia. These collaborations enhance Alvotech’s reach and impact within the healthcare industry.
Frequently Asked Questions
What is the purpose of Alvotech's listing on Nasdaq Stockholm?
The purpose of the listing is to broaden Alvotech's investor base and enhance visibility among institutional investors in Europe.
When will the initial trading of SDRs take place?
The first day of trading is expected to commence on May 19.
How much is Alvotech hoping to raise from this Offering?
Alvotech anticipates raising approximately SEK 30 million through the Offering.
Will current shareholders have the opportunity to convert their shares?
Yes, existing shareholders will have a free conversion period to convert their ordinary shares into SDRs within the first year.
What type of products does Alvotech focus on?
Alvotech specializes in the development and manufacture of biosimilar medicines, targeting various health conditions and seeking to improve patient access globally.
